TriNetX announced it has acquired key assets of Zetta Genomics, strengthening its ability to federate and analyze genomic data across its global network of healthcare providers. The deal builds on an existing partnership between the two companies and expands TriNetX’s capabilities in managing and analyzing multiomic data at scale.
Zetta Genomics’ flagship platform, XetaBase, enables population-scale genomic analysis and is already used by healthcare organizations, life sciences companies, and research institutions. By integrating XetaBase into its ecosystem, TriNetX aims to enhance providers’ ability to combine phenotypic and genomic data, thereby improving clinical research and patient care outcomes.
The companies have collaborated since 2024 on TriNetX’s genomics data program, demonstrating the feasibility of securely querying genomic and clinical datasets in a federated manner. The acquisition builds on this foundation, allowing broader deployment and deeper integration of multiomic data across TriNetX’s network.
TriNetX said the move will also help its life sciences customers conduct large-scale research more efficiently and cost-effectively, while maintaining data privacy by keeping patient data within originating healthcare institutions.
KEY QUOTES:
“Through our partnership activities, led by our Chief Operating Officer Steve Kundrot and team, we have developed deep familiarity with Zetta’s leadership, technological prowess, and fit-for-purpose approach and have been consistently impressed with Zetta’s trusted healthcare provider relationships and robust analytics platform. Welcoming Zetta’s XetaBase platform into the TriNetX ecosystem represents an important milestone for our organization. This acquisition reflects our commitment to advancing multiomic-enabled research and supporting healthcare providers with a practical, localized approach to scaling their data infrastructures.”
Jeff Margolis, Executive Chairman, TriNetX
“Our purpose of driving better human health through data is clearly enhanced by adding the XetaBase technology, as we strongly believe the integration of different data types is essential to clinical and scientific progress.”
Jeffrey Brown, PhD, Chief Scientific Officer, TriNetX
“I am proud of what the Zetta team has built and excited to see XetaBase become part of the TriNetX array of data, software, and intelligence capabilities. From the beginning, our collaboration with TriNetX demonstrated that genomic and clinical data can be securely connected in a federated way at scale. Fully joining forces with TriNetX allows that work to move forward faster and to reach a broader global community of healthcare and research partners.”
Ignacio Medina Castello, Chief Executive Officer And Chief Technology Officer, Zetta Genomics
